Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma

Acta Oncologica

Volumn 52, Issue 6, 2013, Pages 1231-1233

  Tinchon, Christoph ^a   Hubmann, Eva ^a   Pichler, Angelika ^a   Keil, Felix ^b   Pichler, Martin ^c   Rabl, Hans ^d   Uggowitzer, Martin ^d   Jilek, Kurt ^d   Leitner, Gerhard ^d   Bauernhofer, Thomas ^a  

^a General Hospital of Leoben   (Austria)

^b HANUSCH HOSPITAL   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d Department of Pediatrics   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; LETTER; LIVER METASTASIS; LUNG EMBOLISM; MULTIPLE CYCLE TREATMENT; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SURGICAL MORTALITY; ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84880320244     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.771821     Document Type: Letter

References (14)

1. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007; 297: 267-77.
2. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New Engl J Med 2011; 364: 1817-25.
3. Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderlineresectable locally advanced pancreatic adenocarcinoma. BMC Cancer 2012; 12: 199.
4. Callery M P, Chang K J, Fishman E K, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement. Ann Surg Oncol 2009; 16: 1727-33.
5. Eisenhauer E A, Therasse P, Bogaerts J, Schwartz L H, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
6. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al. Borderline resectable pancreatic cancer: Defi nitions, management, and role of preoperative therapy. Ann Surg Oncol 2006; 13: 1035-46.
7. Wang J, Estrella JS, Peng L, Rashid A, Varadhachary GR, Wang H, et al. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 2012; 118: 3801-11.
8. Siriwardana HP, Siriwardena A K. S ystematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg 2006; 93: 662-73.
9. Lu D S, Reber H A, Krasny R M, Kadell B M, Sayre J. Local staging of pancreatic cancer: Criteria for unresectability of major vessels as revealed by pancreatic-phase, thinsection helical CT. Am J Roentgenol 1997; 168: 1439-43.
10. Stokes JB, Nolan NJ, Stelow EB, Walters DM, Weiss GR, de Lange EE, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 2011; 18: 619-27.
11. Willett CG, Lewandrowski K, Warshaw A L, Efi rd J, Compton CC. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 1993; 217: 144-8.
12. Bickenbach KA, Gonen M, Tang LH, O 'Reilly E, Goodman K, Brennan MF, et al. Downstaging in pancreatic cancer: A matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Ann Surg Oncol 2012; 19: 1663-9.
13. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, et al. Borderline resectable pancreatic cancer: The importance of this emerging stage of disease. J Am Coll Surg 2008; 206: 833-46; Discussion 46-8.
14. Papalezova K T, Tyler D S, Blazer D G, 3rd, Clary BM, Czito BG, Hurwitz HI, et al. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? J Surg Oncol 2012; 106: 111-8.